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INTRODUCTION 
 
Vertical and horizontal lines spread over a picture forms a grid to 
permit us close scrutiny of the object in greater detail. The intentions 
behind classification in any system are also to get help in similar ways. 
Still there is a possibility that the ‘whole’ may get blurred when 
prominence is awarded to ‘part’. Attempts to bring clarity in the concepts 
of mental illness, by sharpening the edges of figure and ground has been  
and is being more difficult than comparable trials in other branches of 
medicine. Lots of trimming and pruning by our Psychiatrist ancestors has 
provided us a beaten path to tread, and even given a chance to look 
around and comment on the path itself. 
 
Is the beaten path all that clear? Is Schizophrenia so well different 
from Depression? Some observations made by the senior Psychiatrists 
made this question more relevant. We are still confused with the issue of 
making a diagnosis with no help from the laboratory thus far. One 
psychiatrist makes a diagnosis of depression and the other calls it 
Schizophrenia. What is worse is that the patient improves with either of 
the treatments viz. anti-depressants or anti-psychotics. Then what was the 
problem? 
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One unpublished study from Karolinska University reported 
Risperidone with Escitalopram was as good as Clozapine. But Citalopram 
didn’t do the trick. Centrifugal considerations give us some demarcated 
areas for scanning the relationship between affective disorders and 
Schizophrenia. 
 
PRE-PSYCHOTIC, PSYCHOTIC AND POST-PSYCHOTIC 
 
Pre Psychotic:  
The possibility of affective disorders among the close relatives of 
patients with schizophrenia, turned out to be a significant starting point. 
There was a possibility of two different disorders in the family tree with 
probabilities of a combination. 
It is common talk among psychiatrists about ‘what was apparently 
Depression turned out to be Schizophrenia, during follow-up. The 
tendency to brand in an adolescent an ‘early Schizophrenia’ without any 
feature of that, and in all probabilities deserving a diagnosis of 
depression, is not unknown. 
 
Psychotic Phase:  
The points of contact were many. There can be some mood 
disturbances in Schizophrenia which approximates with Depressive 
symptoms. The so called negative symptoms have much in common with 
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depressive symptoms. The medicines used in the treatment of 
Schizophrenia make the person a ‘zombie’ that he can be mistaken for 
depression. The cognitive deficits often render the patient withdrawn and 
lethargic creating a pseudo depressive picture. Many a step inducting the 
individual to interact with the society may make him acutely conscious of 
his limitations and sprout an adjustment reaction with depressive features. 
The person with paranoid disorder runs a greater risk in that a realization 
that his persecutors are more powerful than him frightens him of the 
consequences and drives him to consider suicide. 
 
Post Psychotic Phase:  
Invariably the possibility of realizing what had happened and the 
knowledge of shameful events that have just receded causing extreme 
sorrow in those with some insight on recovery is the major consideration. 
Another thought process is that there was depression in the person during 
active psychotic process, but shaded from exposure by the umbrella of 
psychotic symptoms. However it was apparent that the depression was 
not only in the immediate post psychotic phase but also extended to 
longer periods. An aggravation of depressive symptoms appeared to 
predict a relapse too. 
Questions keep pouring. If there is Depression in Schizophrenia, - 
will it alter the strategy of therapy? Would this Depression be the cause 
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of alarming rate of suicide in Schizophrenia? Is it beneficial to use a 
dopamine agonist to treat or should we resort to SSRIs? Is psychotherapy 
holding better promises than pharmacotherapy in these conditions?  
With humble intentions to see the light that ought to be at the end 
of the tunnel this small step is taken. 
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REVIEW OF LITERATURE 
 
Though the Kraepelinean dichotomy has remained as a 
monumental sign post directing the passersby over centuries in practice 
and research, it has attracted adequate controversies too.  
There is no questioning of its authority as a guideline. But the 
objection comes from the observation that the divisional criteria are more 
dimensional than categorical. The grouping of variables in varying 
strengths is found inadequate. We need exclusive criteria that can 
separate categories that will not let the variable join hands in differing 
ways to erupt different diagnoses. One such factor is mood incongruent 
delusion favoring Schizophrenia [Kendler, 1986, Peter McGuffin]  
Ian F Blockington is disillusioned with the very concept of 
Schizophrenia which to him is an ‘improbable entity’. He compares it 
with religious faith which can accept eco-friendly changes across 
geographical stretches, for want of concrete concepts [1]
DSM and ICD has promoted with great advantage and remarkable 
clarity from a pool of confusion, checklist type of diagnostic formulation. 
It simply permits to combine opposing entities as co-morbidities, which is 
a gross shift from general principles of Medicine and commonsense 
diagnosis. 
. 
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Is there an association between Depression and Schizophrenia? 
 
Even the original writings of Emil Kraepelin underline depressive 
features in Schizophrenia and Psychotic (schizophrenic) features in 
Depression. Epidemiological studies continue to support the view! 
The prevalence rate for depressive syndrome in patients diagnosed 
to suffer from Schizophrenia has a wide fluctuation in various studies viz, 
7% to78% with a modal frequency of 25%. This difference in inferences 
is attributed to investigator preferences and bias based on defining 
criteria, methodology employed, cohort status, observed interval etc,. 
[Siris 2001, Sands 1999, McGlashan 1976, Elk R1986, Van Putten and 
May 1978,Munro 1984, Leff 1988,Kulhara 1989, Addington and 
Addington 1990, Lindenmayer 1991, Koreen 1993, Mauri 1995, Markou 
1996,Wassink 1999, Muller and Wetzel 1998, Serretti , 2004 ]
A life time risk of 81% for depression in patients with 
Schizophrenia was reported in many studies including The National Co 
morbidity Study [Kendler 1996, Bland 1987; Hafner 1999; Koreen 1993, 
Martin 1985]. A point prevalence of Major Depressive symptoms in 
Patients with Schizophrenia ranged between 10% to 30%.[Baynes  2000; 
Delahanty  2001; Herbener and Harrow 2002; Messias  2001;Jin  2001; 
Hafner  1999] . In the Epidemiological Catchment Area Study, patients 
who fulfilled DSM III criteria for Schizophrenia were found to be 14 to 
[2] 
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28.5 times more likely to have a concurrent major depressive disorder 
than the general population
The attraction of depression to cohabit fair sex in general is known, 
but not equivocally proved when Schizophrenia is present.  
 [3] 
[A Addington 1996; Brunete, 1997; McGlashan and Bardenstein 1990 
Messiahs, 2001; Oosthuizen, 2002][4]
The life time prevalence of a major depressive episode in patients 
with Schizophrenia is around 60%.
.  
 [5]. In a retrospective study conducted 
in 203 patients admitted for their index psychotic episode, it was reported 
that 81% of the patients experienced a depressive episode about four 
years prior to the current admission.
The evidences from genetic studies have not accepted the 
possibility of a pure breed in Schizoaffective disorders. It appears that the 
two disorders breed independently and may co occur by chance. 
[6,7,8].    
Camberwell 
 
Register reports  life time risk of Schizophrenia as 
0.86%; depression of sufficient severity requiring inpatient care as 2.7% 
and upper limit for chance co-occurance  of affective disorders with 
schizophrenia as 3 in10,000. But we have evidences to show that the 
association between depression and schizophrenia is not so rare-ruling 
out the possibility of chance. 
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Now the question is 
Why is depression shaking hands with Schizophrenia? 
The summation of biological, psychological and environmental 
risk factors results in the development of depression in schizophrenia. 
Chronic stress, stigmatization, social isolation, disablement and 
demoralization are known risk factors for depression.  
The devastating nature of Schizophrenia and its social 
consequences means that most patients with schizophrenia are also 
exposed to these psychological risk factors for depression
 
 [9].  
Stress Vulnerability Model [Stress-Diathesis Model]: 
It is based on the concept that genetic factors make an individual 
vulnerable to develop a disease and its interaction with the stressors is the 
mode of operation in disease precipitation. This interaction between 
genetic load and environmental stress gives a product, the value of which, 
while crossing the threshold recruits the subject into psychotic population 
[Zubin 1977].  
The vulnerability is in a continuum, the two ends representing the 
least vulnerable that may never manifest the disorder and the most 
vulnerable who can never escape the disorder. In between lie the majority 
with varying weight of vulnerability requiring appropriate stressor to 
multiply the vulnerability factor to reach the threshold.  
9 
 
The stress factors vary in quality and quantity. They can be 
biological or psychosocial. Given that background, it is possible to 
consider that the stress of depression itself can precipitate an episode of 
Schizophrenia in a vulnerable person with its disturbing influence on 
hormones, monoamines and sleep. It is all the more provoking to support 
this hypothesis when one considers that 
a) Positive symptoms are seen in combination with depression in 
schizophrenia more often than negative symptoms, and 
b) Treatment of syndromal depression with antidepressants 
convincingly postpone the relapse of schizophrenic episode.[10,11]
Depression and Schizophrenia in Family Studies: 
  
There is a considerable overlap between the genetic predisposition 
for affective disorder and schizophrenia [12, 13].A family history of mood 
disorders in patients with Schizophrenia increases their chances of 
developing depressive symptoms. [15, 16, 17]
Crow T.J has suggested a continuum hypothesis- affective 
disorders and schizophrenia lying at opposite poles of a continuum of 
genetic load – the evidences borne by the fact that many relatives of a 
proband with schizophrenia manifest affective disorder. He suggests the 
possibility of lesser genetic load representing affective pole and a severe 
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genetic modification tilting the psychotic pole [18]
The researchers have come up with innumerable explanations 
about the cause of depression in schizophrenia. Some feel that it is the 
interference produced by neuroleptics on the dopamine reward pathway 
that is responsible for appearance of the symptoms
. This may be compared 
with Slater’s observation [Slater E 1947] that the parents of many of his 
patients with schizophrenia had depressive features in the absence of 
psychosis. That the parents who could go on to reproduce had a lighter 
load of schizophrenic genetic material which could have manifested as 
phenotype depression of genotype schizophrenia is a plausible 
explanation. 
 [19]
Is Depression in Schizophrenia due to impact of pharmacotherapy?  
. 
The answers ‘yes’ and ‘no’ are found, with the negative statement 
adding value to the existence of depression in Schizophrenia. The concept 
that a prodromal state presents with symptoms indistinguishable from 
depression rules out pharmacogenic influence in that presentation 
[Conrad; Herz and Melville 1980]. The finding that neuroleptic treatment 
and even Chlorpromazine has helped to improve depressive symptoms in 
Schizophrenia is significantly amalgamating these depressions with 
Schizophrenia. [Rifkin A, 1975; Siris SG 1987; Bermanzohn, 1992; Van 
Putten T 1978] 
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The concept of ‘Akinetic Depression’ [Van Putten and May 1978] 
is elusive, in that many authors have found anticholinergic therapy had no 
more effect than placebo in treating those symptoms [Moller and Zerssen 
1981; Johnson 1981].  
Depression lifting with antipsychotic therapy gives little chance to 
consider ‘revealed depression’ which would have remained onstage after 
antipsychotic therapy. Post psychotic depression has no correlation with 
neuroleptic medication, and it is recognised as a psychosocial reaction to 
the awareness of the burden of illness. The term ‘Aphanisis’ introduced 
by McGlashan refers to residual defects of schizophrenia that may be 
confused with depression.
Post Psychotic Depression:  
 [20] 
            Roth opined that the patient’s failure in some facet of human 
relationship results in the psychobiological reaction which manifests itself 
as post psychotic depression. In other words, he felt that it was the 
patient’s reaction to the losses he experienced due to the psychotic 
process. 
          Whether the depressive symptoms in post psychotic depression 
have their onset in the post psychotic period or whether these symptoms 
are unmasked when the psychotic symptoms remit is still under debate. 
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          Reports of positive correlation between the depressive symptoms 
and the positive symptoms of Schizophrenia and of the good response of 
the depressive symptoms to antipsychotic medication are in favour of the 
latter hypothesis [21]
Reactions to Disappointment and Stress:  
. 
 The reactions to disappointment and stress can be either acute or 
chronic.  
 Acute reactions leave a traceable track that lead to this reaction 
from losses, disappointments or bereavement in the recent past. By 
definition they are short lived. 
 On the other hand Chronic Demoralisation is a state of severe 
hopelessness due to real problems that are recurrent or continuous [Frank 
and Klein]. The culprit in this case is the awareness of the problem. In 
premorbid high achievers, perceptions of the devastating influence of the 
psychosis on their life can drive them to desperate levels. Those who 
realise the limitations and humiliations the psychosis can inlay in every 
aspect of their life are more prone among the patients with Schizophrenia 
to develop this syndrome. This is different from the neuro-endocrinal 
dysregulation of syndromal depression and notably differs from that by 
the absence of vegetative symptoms. Hence it responds better to 
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psychosocial remediational approaches than somatic therapies. It is 
important to recognize this group since they run a high risk of suicide[22]
Yet another group feels that alcohol and other substance abuse 
patterns which are commonly co morbidities in schizophrenia may be the 
culprits in the evolution of depressive symptoms in these patients. 
.  
A large group argues that depressive symptoms are in fact core 
features of the schizophrenic phenomenology itself. This thought gains 
strength from the finding that depressive features are present in the acute 
stage of the psychosis and often stand side by side with positive 
symptoms. Further they often remit with anti psychotic therapy. 
Depression as an intrinsic part of the Acute Psychotic Episode: 
            Depressive symptoms occurring simultaneously with the 
psychotic symptoms are viewed by some researchers as a core symptom 
of schizophrenia. This gave rise to the five dimensional theory of 
schizophrenia where schizophrenia is postulated to have positive 
symptoms, negative symptoms, disorganised thought, hostility/ 
impulsivity   and anxiety / depressive symptoms. [Moller 2005]
            Yet another dimension of thinking is that depressive symptoms 
may be co-morbidity. 
[21] 
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Though there is a large diversity in the arguments put forward, the 
general weightage over time has been for the stress vulnerability model. 
When does Depression occur in Schizophrenia? 
Before, During and After! 
1. Depression as a prodromal feature 
2. Depressive symptoms as prominent component of acute episode 
3. Post psychotic depression 
This last one can be further classified as early post psychotic 
depression and late post psychotic depression 
a. Early post psychotic depression:  
This refers to depressive symptoms appearing within 6 months 
of acute episode of psychosis. Considering the possibility of confusion 
with residual psychotic symptoms, atypical antipsychotics can be 
considered as treatment option. An antidepressant can be added if the 
depressive symptoms are severe and persistent even after treatment 
with an antipsychotic. 
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b. Late post psychotic depression: 
 This appears more than 6 months after the acute episodes. Here an 
antidepressant like SSRI should be considered as first line of 
management. 
In the Indian scenario, SS Raju conducted a study on the co- 
morbidity of depressive symptoms in patients with schizophrenia. At the 
time of recruitment, 34 % of patients were found to have depressive 
symptoms. With 8 weeks of neuroleptics, depressive symptoms abated in 
47% of these patients.  
These patients were followed up for the next 48 months. 
• 10% of patients developed Major Depressive Disorder in the 
presence of residual symptoms. 
• 25% of patients developed depressive symptoms not amounting to a 
syndrome in the presence of residual symptoms 
• 3% developed schizoaffective disorder 
• 2% of patients in whom symptoms of schizophrenia had remitted 
developed major depressive disorder. 
• 53% of patients who developed depressive symptoms on follow up 
had no such symptoms at the onset of schizophrenic illness.[23] 
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How does depression manifest in the stage of Schizophrenia? 
The depressive symptoms in Schizophrenia may either qualify for a 
syndrome in itself or it may be present in subsyndromal proportions. 
• Co morbidity – as a syndrome 
• Subsyndromal 
Along the longitudinal course of schizophrenia, the depressive 
symptoms may emerge at various time periods. The significance, effects 
and treatment of the depressive symptoms vary based on the time period 
when the depressive symptoms first make their debut. [SIRIS SG 2001] 
 
Differential Diagnosis     
Depressive symptoms in schizophrenia are usually under reported 
and under recognised, making the diagnosis of depression in 
schizophrenia a diagnostic challenge. Various disorders have been 
recognised which can produce symptoms mimicking depression in 
schizophrenia. Some important differential diagnosis for depression in 
schizophrenia is the side effects produced by conventional antipsychotics 
like akinesia, akathisia and drug induced dysphoria. 
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The depressive symptoms as such may be due to various reasons as 
suggested by Bartels and Drake in 1988,
• Depression may develop secondary to organic factors. 
 [24] 
• Depression may be intrinsic to the acute psychotic episode. 
• Depression which is separated from the psychotic episode 
temporally, like depression in prodrome, post psychotic depression 
etc.          
Depressive symptoms that are secondary to Medical and Organic 
factors: 
Various medical and organic factors can produce symptoms of 
Depression in a patient with Schizophrenia. This includes pulmonary 
infections, neurological, cardiological, metabolic or endocrine disorders, 
anaemia, cancer and autoimmune diseases. Certain drugs used in 
treatment such as beta blockers, non-steroidal anti-inflammatory drugs, 
indomethacin, sulphonamides, anti-neoplastics, sedative hypnotics and 
barbiturates can cause depressive symptoms. Discontinuation of cortico-
steroids or psycho stimulants can also produce similar symptomatology. 
Abusing substances like alcohol, cocaine, cannabis or narcotic substances 
can also cause depressive features. Abstaining from regular supply of 
legal substances like caffeine and tobacco, often on medical restrictions 
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as in many in-patient units may pose an added reason to mimic 
depression
Neuroleptic Induced Dysphoria: 
 [24] 
Dopamine blockade in the meso-limbic pathways by conventional 
neuroleptics can lead to anhedonia and depression. If Schizophrenia is 
conceived as the state of Dopamine dysregulation, the positive symptoms 
may reflect the storms of dopamine and the negative symptoms the 
droughts. Then it will be reasonable to see that slight excess of 
neuroleptics in therapy can bring down the affect to get a label –
neuroleptic induced depression. Drug induced dysphoria has been one of 
the causes behind poor compliance in patients with Schizophrenia. 
However, the results from most studies remain controversial till date. 
[Buckley, 2009; Hausmann A, 2002; Siris SG 2003, DJ King, 1995]. 
Many depressive features remit along with psychotic symptoms during 
the treatment with neuroleptics. 
Akinesia: 
Akinesia is induced by antipsychotic medications and it can present 
in a blatant or subtle form. In the blatant form, the patients present with a 
Parkinsonian gait, stooped posture and diminished arm swing. This is due 
to the involvement of large muscle groups. 
19 
 
The subtle form of akinesia is easily confused with depression. It 
involves the small muscle groups. Involvement of facial muscles 
produces a lack of facial responsiveness which is confused with a low 
mood. It also impairs the patient’s ability to initiate and sustain motor 
activities [25]
Many anti-parkinson drugs like Levodopa, Seligiline and 
Pramiprexole are known to have antidepressant properties though to a 
lesser degree. 
. This may be mistaken for the psychomotor retardation of 
depression. Patients with akinesia are prone to dysphoria [Rifkin A , 
1975]. It was Van Putten who introduced the term “akinetic depression” 
to describe a patient with akinesia, blunted or depressed affect and apathy 
[Van Putten 1978]. The addition of  anti-Parkinsonian medication results 
in a dramatic improvement in these patients,[Van Putten 1987,Siris SG ]. 
While the effect is not so evident in depressive symptoms, there are 
indeed studies which have pointed to positive results in patients with 
depression when treated with Trihexyphenidyl. 
Akathisia: 
This is another movement disorder that can be triggered by 
moderate dose of high potency antipsychotic medications [Van Putten, 
1985]. This also has a blatant and a subtle variety. In the blatant variety 
the patient often paces and has difficulty remaining seated. The subtle 
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form is not so dramatic and the patients may merely talk excessively or 
wander. This presents a picture simulating the psychomotor excitement or 
agitation which may be a part of depression. Akathisia also has a 
dysphoric component in which the patient appears agitated or restless and 
may be mistaken to have agitated depression. Akathisia produces an inner 
sense of restlessness which when paired with a profound dysphoria, may 
culminate in suicides and homicides. [Shear k, 1983; Schulte JR, 1985; 
Drake RE, 1985] 
Negative Symptoms of Schizophrenia: 
Many features of negative symptoms of schizophrenia are identical 
to depressive phenomenology. The lack of initiative, social withdrawal, 
anhedonia, reduced speech and activity can be easily mistaken for 
depression. Differentiating between negative symptoms and depression 
often poses a diagnostic challenge. However the salient features of 
depression such as depressed mood, pessimism, guilt and suicidal 
thoughts help to differentiate it from the negative symptoms of 
schizophrenia. 
Schizoaffective Disorder: 
 The term schizoaffective psychosis was first coined by Kasanin. 
He used this term to describe a psychotic disorder with an amalgam of 
21 
 
affective and schizophrenic symptoms. Patients with schizoaffective 
depression are difficult to distinguish from the patients exhibiting 
depressive symptoms in schizophrenia. However in schizoaffective 
depression, the depressive symptoms must fulfill the criteria for a major 
depressive disorder. Genetic studies do not support the view that schizo 
affective disorder can be a pure breed. McGuffin P et al 1982 report on 
three sets of triplets. They had a mixture of  Manic Depressive Psychosis 
or Schizophrenia in pure form and only one had indication of 
schizoaffective disorder. Twin studies of probands suffering from 
schizoaffective disorder too did not support the possibility of 
schizoaffective disorder as a heritable pure form. Studies vary with 
relatives in some having affective disorders more often and others picking 
schizophrenia with preference. In one study of Schizophrenia and Manic 
DepressivePsychosis marriages there was no intermediate form. Probably 
it is always a chance occurrence and not a true breed [26,27]
Prodrome of Psychotic Relapse: 
.  
 Depressive symptoms frequently precede relapse. [Donlon and 
Blacker; Docherty]. The symptoms of dysphoria, agitation, anxiety, 
inability to concentrate, social withdrawal, lack of appetite and lack of 
sleep were noticed to occur quite frequently in the early stages of 
psychotic decompensation. These usually last for few days before they 
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are over taken by the psychotic upheaval. The onset of the symptoms is 
sudden and more like an Agitated Depression in contrast to Depressive 
syndrome. Family members will be able to identify the symptoms easily 
and hence psycho- education can help to initiate treatment early and nip 
the psychotic symptoms.  
Post Psychotic Depression:  
 This diagnosis is reserved for depressive episodes occurring in the 
aftermath of a psychotic illness. This has been regarded as the natural 
consequence of recovery from an acute psychotic episode, at which time 
the patient becomes aware of the events of the psychosis and develops a 
reactive depression. 
Reactions to disappointment and stress:  
As discussed earlier, the reactions to disappointment and stress can be 
either acute or chronic.  
 Acute reactions leave a traceable track that lead to this reaction 
from losses, disappointments or bereavement in the recent past.  They are 
fairly short lived. 
 Chronic Demoralisation , as discussed earlier is a state of severe 
hopelessness in premorbid high achievers due to perceptions of the 
devastating influence of the psychosis on their life  [22].  
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Depression that is intrinsic to the Acute Psychotic Episode: 
 Among the various considerations the most parsimonious view of 
why depression is so prevalent among patients with Schizophrenia is that 
like the positive symptoms and negative symptoms which are part and 
parcel of Schizophrenia, depressive symptoms are also a part of the 
natural course of Schizophrenia [28]
What are the implications? 
.  
Impact of Depression on Schizophrenia: 
Prognosis:  
 Bleuler viewed depressive symptoms in schizophrenia as a 
positive prognostic indicator. Few researchers like Semrad equated the 
appearance of depressive symptoms to the development of a higher level 
of psychological defence mechanism which opened new avenues for 
psychotherapy [Semrad EV 1966].Many clinicians since then believed 
that the appearance of depressive symptoms in schizophrenia signals the 
process of recovery [Langfeldt G,1937,Roth S,1970]. However the 
literature in this aspect is somewhat divided. Few investigators have 
found depressive symptoms to be predictive of a better outcome [Kay SR 
1987,Vaillant GE 1964] but some have found them to be negative 
prognostic indicators [McGlashan ,1976; Mandel Mr ,1982].  
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 Depression in chronic schizophrenia seems to be an unfavourable 
sign and it has been found to be associated with a greater risk of relapse 
[Johnson DAW,1988; Mandel MR 1982, Herz MI 1980,1985 ; 
Himmelhoch 1981] and suicide [Siris SG,1991,2001; Drake RE ,1986; 
Caldwell CB,1990; Cohen LJ ,1990; Roy A 1982; Black BW 1985]. 
Depressive symptoms have been found to be associated with impairment 
in everyday functions [Glazer W 1981; Serban G 1979 ; Cohe C  
2000],poorer quality of life, increased rates of hospitalisation [Johnson 
DAW 1981 ; Falloon I , 1978] and suicides. 
  This division in literature may be due to various reasons, 
including the differences in defining depression, different patient 
population [acute versus chronic] and different levels of psychosis. 
Predicting Relapse:  
 Statistically significant correlation was found between the severity 
of depressive symptoms and the frequency of relapse in schizophrenia 
[Johnson DA 1988] [29]. Ander Heiden W reported in his study that the 
correlations between the amount of depressive symptoms during a 
psychotic episode and the frequency of relapses were found to be 
statistically significant.
 
 [30] 
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Suicide: 
Schizophrenia has an augmented risk of both depression and 
suicide. It has been estimated that 10% of patients with Schizophrenia 
commit suicide [57]
Risk of suicide is particularly high in depressed patients with 
Schizophrenia in the first few months after diagnosis and after discharge 
from the hospital. Hopelessness as a symptom is a strong contributor to 
suicidal behaviour in patients with Schizophrenia. [Virkunnen 1976; 
Drake 1986] According to Beck, hopelessness has been shown to co-
relate with suicidal intent, and subsequent suicide. 
. People suffering from schizophrenia who exhibit 
suicidal behaviour, both attempts and completions, are found to have 
significantly more depressive symptoms.  Perhaps the most frequently 
identified risk factor for suicide in Schizophrenia is the appearance of 
depressive symptoms. [Beisser and Blanchette 1961; Niskanen 1974; 
Achte 1966; Sletten 1972] The greater parts of patients with 
Schizophrenia who commit suicide have experienced depression before 
the attempt. [Cohen, 1964; Roy 1982]  
There is a high level of subjective distress reported by patients 
suffering from schizophrenia, who attempt suicide [Cohen,]. The 
subjective distress experienced by these patients may go unrecognized by 
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their clinicians perhaps ascribed to psychosis or neuroleptic treatment 
rather than a distinguishable affective syndrome per se. 
Specific treatment of affective symptoms in Schizophrenia helps in 
suicide prevention [31]
Suicide victims among patients with schizophrenia were achievers 
premorbidly, and they had high aspirations against a backdrop of painful 
awareness of their illness. [Drake 1984].  
.  
Among the various subtypes of Schizophrenia, patients with the 
paranoid subtype were found to be more likely to attempt suicide as they 
tend to be more rigid about their original expectations and usually 
perceive their difficult prospects for the future much more clearly. These 
patients have an inherent inclination to project their fears and feelings of 
despair on the world in general. These patients may be obdurate about 
possible options for the future and tend to look at suicide as the only 
option to end their anguish. [Jerry F.Westermeyer and Martin Harrow]  
 
Social Functioning: 
Social functioning is grossly impaired in patients with 
schizophrenia. The appearance of depressive symptoms in Schizophrenia 
further impairs the social functioning. Studies have documented that 
depressed mood surpassed all other symptoms in schizophrenia in 
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contributing to the decline in social function. [Glazer, 1981; 
Serban,1979]. Participating in social leisure activities and the 
performance of social roles were particularly affected [32]. Greater degree 
of insight has been found to be a contributing factor for the poor quality 
of life in these subjects [33]
A strong association has been found between change in functional 
outcomes and change in depression status in long term treatments of 
patients with schizophrenia. Hence paying special consideration in 
treating the depressive symptoms in patients with schizophrenia can go a 
long way in recovering their overall functioning 
.  
[34]
Siris , reported that the longitudinal studies exploring the course of 
schizophrenia have found depressive symptoms to be rampant during all 
stages of schizophrenia. Evidence suggests that depressive symptoms are 
associated with impairment in everyday functions, poor quality of life and 
greater need for medications and hospitalization. Siris, has reported that 
depressive symptoms increase mortality rates in these patients by 
contributing to their high rate of suicide.  
.  
Impaired Memory: 
The appearance of depressive symptoms in schizophrenia has been 
found to have a negative impact on the person’s memory functions. [Burt 
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DB, 1995]. The encoding process in the organisation of memory becomes 
deficient in these patients. [Weingaartner H 1986]. The degree of memory 
impairment has been found to be positively correlated with the severity of 
depressive symptomatology. [Smith MJ, 1994][35]
Which factors overlap and smudge the picture? 
. Evidences suggest that 
the decreased left prefrontal lobe function in schizophrenic patients may 
be responsible for the appearance of depressive symptoms and memory 
impairments in schizophrenia. [Fletcher PC 1995, Dolan RJ 1993]. 
Treatment with anti psychotics has not produced significant improvement 
in memory and it has been proposed that the addition of an antidepressant 
might be beneficial. 
Negative symptoms and Positive symptoms 
 Though phenomenologically the depressive symptoms seem to 
mimic the negative symptoms, studies are not in favour of a positive 
correlation between these two variables. On the contrary, positive 
symptoms have been demonstrated to have a positive correlation with 
depressive symptoms appearing in these patients [Zisso ,1999;Norman 
and Malla , ,1991;Sax KW ,1996 ; Barnes , 1989 ; McKenna PJ,1989; 
Prosser ES, 1987; Hirsch SR,1989][36,37].  
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 In a study by Kulhara, it was seen that the characteristic 
symptoms of depression other than retardation, slowness and lack of 
energy had poor to negative correlation with negative symptoms [38]. 
Tharyan and Kuruvilla studied the correlates of depressive symptoms in 
patients with schizophrenia and found that retained insight and lower 
negative symptom scores were more common accompaniments of a mild 
depressive state developing in these patients 
 Individually, various psychotic symptoms have been linked 
with a raised risk of emergent depression. Studies of the phenomenology 
of depression have discovered that between 66%- 75% of persons with 
auditory hallucinations will exhibit at least moderate depressive 
symptoms due to the experience [Chadwick, Brichwood 1994, 1997; 
Trower, 2004]. The presumed threat from persecutors is enough to 
generate depressive symptoms, particularly if the person feels vulnerable 
and exposed. Studies by Norman and Malla and Hirsch, emphasise that 
there is a positive correlation between depressive symptoms and positive 
symptoms of schizophrenia
[39].  
 [40]
 Norman and Malla have suggested that in the relationship 
between depressive symptoms and the positive symptoms of 
Schizophrenia the most robust feature is the association between 
depressive symptoms and reality distortion. The left medial temporal 
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lobe, the origin of reality distortion with its close link to the limbic 
system explains the coupling.  
 Baynes, in their study found that persistent depressive 
symptoms are related to the degree of persistent positive symptoms and 
the patient’s perception of the extent of social support
Extra pyramidal symptoms: 
 [58] 
Though there is an apparent phenomenological overlap between the 
depressive symptoms and extrapyramidal symptoms, no positive 
correlations have been documented. 
Insight: 
Tharyan and Kuruvilla found that retained insight is one of the 
factors associated with the development of depressive features in 
schizophrenia. It has also been shown that during acute schizophrenia, the 
insight will not be lost completely [ Brichwood , 2000] and this available 
insight may be adequate to trigger a depressive reaction if the patient’s 
appraisal of the illness is associated with ‘shame’, ‘loss’, and 
‘entrapment’. Tania, found that insight was related with increased suicidal 
ideation or actions. Increase in insight was found to cause increase in 
depressive symptoms.  
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Apart from this, studies have shown that the treatment of patients 
with schizophrenia with insight -focused CBT and non-CBT approaches 
targeting insight increased the incidence of depression in these patients[41, 
42] .
 
          
Atypical antipsychotic: 
There are various reasons why the presentation of depression in 
schizophrenia treated with atypical antipsychotic is different from 
Schizophrenia treated with conventional neuroleptics, although this needs 
to be confirmed by careful investigations. The incidence of akathesia, 
akinesia, and drug induced dysphoria and negative symptoms which are 
very close differential diagnosis of depression in Schizophrenia are much 
less in patients treated with atypical antipsychotics. [Tandon R , 1997; 
Marder , 1994; Jones H , 1997; Meltzer HY , 1989;Tollefson , 1997; 
Beasley , 1996] The quality of life measures have also been found to be 
superior in patients on atypical antipsychotics and hence reactions to 
stress may be reduced.[Tollefson GD , 1999,Franz M , ,1997] Various 
studies have reported that atypical antipsychotics have direct 
antidepressant effect [Azorin ,1995,Tran ,1997; Tollefson ,1999,Beasley 
1996, Keck , 1998; Emsley , ,2003]. In addition clozapine has been found 
to have antisuicidal properties.[Walker ,1998; Meltzer ,1995 ] 
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What are the specific tools for assessment?  
The Calgary Depression Scale for Schizophrenia [CDSS] was 
developed by Addington, specifically for assessing the depressive 
symptoms occurring in patients with Schizophrenia
Collins demonstrated that this scale is methodologically superior 
when compared to other scales like HAM D and Becks Depression 
Inventory.
 [43]  
What are the implications in treatment when Depression is with 
Schizophrenia? 
 [44] 
The first step in the treatment of depression in schizophrenia is 
considering the possible differential diagnosis.  
The second step is to exclude organicity. 
In the event of recent onset depressive reaction, the various 
possibilities which have to be considered after excluding organicity are an 
acute stress reaction or the prodrome of a psychotic episode.  
If the patient is at high risk of suicide, he may require 
hospitalisation. In all other cases, the most appropriate initial response is 
to increase surveillance, provide additional support and reassess the 
patient after a week.  
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An acute stress reaction will resolve spontaneously, and an 
incipient psychotic episode will soon manifest itself. In the latter case, the 
psychotic episode can be promptly treated with appropriate antipsychotic 
agent. 
If at the follow –up visit, patient’s depressive symptoms persist but 
psychotic symptoms have not progressed, evaluate for possible extra-
pyramidal features which may be subtle and difficult to rule out. If the 
patient is restless and there are features of akathisia, a trial of 
benzodiazepine can be given.  
If the patient is hypoactive, consider a trial of an anticholinergic 
anti-Parkinsonian agent, such as Benztropine, for akinesia.  
After ruling out extra-pyramidal symptoms, the next possibility to 
be considered is antipsychotic – induced dysphoria. In this case the 
neuroleptic dose can be decreased after making sure that there are no 
active psychotic symptoms.  
The other option is substituting the conventional neuroleptic with 
an atypical antipsychotic. Various studies have shown that the atypical 
antipsychotics have antidepressant property. Marder, in 1997 did two 
double blind studies which showed that Risperidone produced greater 
reduction in depressive symptoms when compared to haloperidol [45] 
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Olanzepine was found to be superior to haloperidol in bringing down 
MADRS scores in a prospective study conducted by Tran, and Tollefson 
[46]. Similarly Quetiapine was also found to be more effective than 
conventional neuroleptics in treating depressive symptoms in 
Schizophrenia [Emsley, 2003] [47]. Treatment in neuroleptic resistant 
patients with Schizophrenia with Clozapine has evidenced a drop in the 
suicide attempt rates from 25% to 3.5 %[ Meltzer and Okayli] [48] 
In circumstances where the episode of Depression persists in a 
patient who is already on treatment with atypical antipsychotic, the 
existing literature does not give much guidance regarding the further 
management. Among the atypical antipsychotics, Risperidone is known 
to have mild Parkinsonian effect .Hence if the patient is on Risperidone, 
the dosage can be tapered or an anti-Parkinsonian drug can be added. 
Substituting an atypical antipsychotic for another is the other possibility. 
Care should be taken to see to it that anticholinergic drugs are not 
combined with Clozapine because it may produce severe autonomic side 
effects. 
Walker, 
also reported a significant decrease in suicidality with Clozapine.  
If the depression still persists, consider adding an adjuvant 
antidepressant medication. Both tricyclic antidepressants [49] and Selective 
Serotonin Reuptake Inhibitors [50] have been found to be effective as 
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adjunctive antidepressants [Hogarty GE, 1995; Siris SG 1994; Singh AN 
1979 ] . With tricyclic antidepressants, the central and peripheral 
anticholinergic effects like urinary retention, constipation, delirium and 
cognitive dysfunction may be particularly troublesome. The 
antiadrenergic effect of these drugs produce postural hypotension and 
their antihistaminic effects produce sedation. SSRIs are relatively safe 
even in overdose situations [51] 
Based on their study, Koreen et al, opine that in patients with acute 
schizophrenia, most of the depressive symptoms remit with the 
antipsychotic treatment and that the addition of an antidepressant might 
retard the antipsychotic response to the neuroleptic drug. They feel that 
antidepressants should be limited to patients who continue to have 
depressive symptoms even after the psychosis has remitted.
and hence safe with potentially suicidal 
patients.  
Prescribing antidepressants concurrently with antipsychotic 
medication is a common clinical practice [11% to 43%]. At times the 
antidepressants have been found to aggravate the psychotic symptoms 
[Prusoff 1979]. In a study conducted by Maria Ladea in 2010, it was 
reported that Escitalopram and Venlafaxine proved to be safe when used 
along with antipsychotic medications in patients with schizophrenia. 
 [52]  
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In few reports, lithium has been reported to have a favourable 
outcome. Lithium augmentation would be helpful for dealing with 
suicidal ideation. The positive outcome has been particularly seen in 
patients who had previous affective episodes, a family history of affective 
disorder or an overall episodic nature to the clinical course. However 
more research is needed since the evidence supporting the use of lithium 
in these patients is generally lacking. 
Determining the temporal appearance, duration, quality and 
severity of depressive symptoms is necessary for diagnosis and 
formulation of an appropriate treatment plan. It was estimated that 38% 
of all subjects entering the CATIE for treatment of schizophrenia were 
being treated with a concomitant antidepressant. There is evidence to 
support the use of these drugs in this co morbid state, although most 
randomized trials in this area are neither large nor of the highest quality. 
[Psychol med 2003]  
Though it is true that there are evidences supporting the use of 
adjuvant antidepressants, researchers feel that their use should be limited 
to cases where an optimal dose of neuroleptic and a trial of atypical 
antipsychotic have been inefficient [53]. 
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Even with pharmacotherapy, some symptoms tend to remain. 
Psychosocial therapies have been shown to be effective in alleviating 
these residual symptoms and improving the social functioning and quality 
of life. Hence attempts to augment the treatment with a combination of 
various psychotherapeutic modes are called integrated psychological 
therapy. [K.Felmet,]
The various components of the psychosocial therapies include 
psycho education, social skills training, assertive community treatment, 
family intervention, cognitive remediation and cognitive behavioural 
therapy. It is observed that each component of psychotherapy has specific 
domains e.g: understanding symptoms and nature of the disorder; social 
skills training to enhance social interaction and facilitate job 
opportunities; Family therapy to correct expressed emotions, therapy 
adherence and prevention of relapse; cognitive remediation to improve 
neurocognitive functioning. Integrated Psychological Therapy [IPT] has 
been found to be beneficial in patients with depressive symptoms in 
schizophrenia.  Change, even in a positive direction can be stressful and 
hence patients with Schizophrenia benefit from nonspecific support and 
psychosocial rehabilitation services
[54]. 
[55] .Though gender differences have 
not been reported as a factor influencing treatment response, one study 
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reported the females to benefit more from pharmacotherapy [Hogarty , 
1995; Massimo C , 2008].[56]
An ‘International survey of Depression in Schizophrenia’ was 
carried out by D. D. Addington, to evaluate the clinical approaches in this 
area. Though majority of respondents acknowledged the considerable 
clinical burden of depressive symptomatology in Schizophrenia, there 
was however, little agreement on the best management strategy.
  
 
 [59] 
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AIMS & OBJECTIVES 
With this background the current investigation aims at observing,  
1.  The frequency of depressive symptoms at a point in time in patients 
with Schizophrenia.  
2.  To analyze the pattern of depressive phenomenology in relation to 
the different stages of the illness and schizophrenic symptomatology.  
3.  To understand the depressive symptoms on the background of 
Deficit syndrome and drug induced EPS.  
4.  To observe the relationship of depressive features with insight and 
functioning.  
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HYPOTHESIS 
1. There is a positive correlation between CDSS/HAMD scores and 
scores on positive symptoms scale of PANSS. 
2. There is no positive correlation between CDSS/HAMD scores and 
scores on negative symptoms scale of PANSS. 
3. Significant number of patients with Schizophrenia have symptoms 
of Depression when compared to standardized general population 
statistics. 
4. There is a significant positive correlation between CDSS/HAMD 
scores and age in patients over 50 years of age. 
5. There are no correlations between scores on CDSS/HAM D and 
scores on EPRS. 
6. Patients on atypical antipsychotic for more than a month have low 
scores on CDSS scores than patients who have been on typical 
antipsychotic. 
7. There is a significant positive correlation between higher scores on 
Schedule for Assessment of Insight [SAI] and CDSS scores. 
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8. Prevalence of Depressive symptoms in Schizophrenia is higher in 
patients who have a positive family history of mood disorder or 
suicide or alcohol dependence. 
9. There is a positive correlation between scores on GAF and CDSS 
scores. 
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MATERIALS AND METHODS 
The study was carried out at The Institute of Mental Health, Chennai. 
Sample Size – 80 subjects 
Sampling Method – Consecutive patients coming to the Out Patient 
Department who fulfilled the inclusion criteria were included in the 
study. 
Study Design - Cross-Sectional study  
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Inclusion Criteria:   
1. DSM IV TR criteria for schizophrenia at the time of assessment.  
2. Age between 18 to 60 years. 
3. Both genders. 
4. Patients with all the subtypes of schizophrenia who are 
cooperative for interview and assessment.  
5. Patient and relative giving consent.  
Exclusion Criteria:  
1. Any axis-I disorders other than schizophrenia. 
2. Co-morbidities like Diabetes, Hypothyroidism, and Dementia. 
3. Patients on Anti-depressants. 
4. Mental retardation as per DSM IV TR. 
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Instruments: 
A semi-structured proforma was administered for all the subjects 
after getting an informed consent. The proforma contains the 
demographic profile of the patient, family history and illness 
characteristics. 
All the subjects were administered the following instruments at the time 
of recruiting the subjects for this study. 
1. Positive And Negative Symptom Scale 
2. Calgary Depression Scale for Schizophrenia 
3. Hamilton Depression Rating Scale 
4. Extra pyramidal Symptom Rating Scale  
5. Schedule for Assessment of Insight 
6. Global Assessment of Functioning Scale 
1. PANSS: 
     This scale was developed by S.R. Key, This 30 item scale was 
specifically developed to assess individuals with Schizophrenia. It 
consists of  a semi-structured clinical interview.  
This scale has thirty items. A seven point continuum is used to rate 
the 30 items. This scale was devised following extensive research and it 
has included essential elements from other important scales. Eighteen 
items from the Brief Psychiatric Rating Scale [BPRS] [Overall and 
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Gorham 1962] and 12 items from the Psychopathology Rating Scale 
[PRS] have been included as a part of this scale [Singh and Kay 1975a]. 
Alpha-Co-efficient analysis has indicated high internal reliability among 
PANSS items with co-efficient ranging from 0.73 to 0.83[P<001] for 
each of the scales. The split half reliability of the general 
psychopathology scale was demonstrated to be 0.80[P<001]. 
The final score of PANSS is arrived at by summation of ratings 
across items so that the potential ranges are 7- 49 for the positive and 
negative scales and 16 to 122 for the General Psychopathology Scale. The 
composite Scale is calculated by subtracting the negative from positive 
score, this yields a bipolar index that ranges from -42 to +42. 
 
2. Calgary Depression Scale for Schizophrenia [CDSS]: 
     This scale is developed by Donald Addington. The Calgary 
Depression Scale for Schizophrenia [CDSS] is a nine item scale which 
was developed specifically to assess Depressive symptoms in 
schizophrenia. It has been extensively evaluated and appears sensitive to 
change. The differentiation of depression from negative symptom and 
extra-pyramidal side-effects of neuroleptic medication is a challenge. 
Previous studies have shown that it is reliable and valid, particularly in 
assessing depression regardless of negative symptoms and extra 
pyramidal side-effects. In contrast to the Hamilton Depression Scale, it 
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has fewer items and considerably less overlap with the positive and 
negative symptoms of Schizophrenia. Items do not focus on weight 
change and initial insomnia, both of which can be confounded by the 
drug treatment of Schizophrenia.  
Score above 6 points on the CDSS has been proposed to separate 
schizophrenia patients with depression from those without depression; a 
further study has found optimal cut-off Values of at least 7 points as 
related to major depression and CDSS scores of at least 4 points to detect 
minor depression in schizophrenia patients. However, studies directly 
comparing the accuracy of the CDSS and the HDRS for separating 
clinically graded mild, moderate, and severe depression in schizophrenia 
is still lacking. 
All items are rated on a four-point scale: 
0=absent 
1=mild  
2=moderate  
3=severe.  
The first eight items are rated on the basis of the patient's responses 
to questions; the ninth item is based on the clinician's assessment of the 
patient over the course of the interview. 
The Calgary Depression Scale for Schizophrenia serves as the most 
appropriate instrument for a dimensional assessment of depressive 
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symptoms in Schizophrenia. However the earlier scales like HAM-D are 
also being used in various studies. 
Receiver Operator Curve for Prediction of Major Depressive 
Episode:   
CDSS Score  Specificity%  Sensitivity% 
           5             74               100 
           6             77                 92 
           7             82                 85 
           8             91                 85 
           9             94                 69 
          10            97                 69 
          11            98                 62 
          12            99                 54 
          13           100                54 
[Addington D, Br J Psychiatry [Suppl 22] 1993; 163 [Suppl 22]  
 
3. HAM-D: 
This scale was developed by A Hamilton. This scale has been 
widely used to measure the symptoms of depression. HAM-D is an 
observer rating scale consisting of 17-21 items.  
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Ratings are made on the basis of the clinical interview and other available 
information .This scale is very effective in detecting the somatic 
symptoms of depression. 
Many versions of the HAMD have been made, but probably the 
most popular is based on 17 variables. Some variables are graded on a 
scale of 0-4and others on a scale of 0-2. 
The HAM-D version with 17-items, has a mean reliability of 
[0.81], the 21-item version exhibits a mean reliability only slightly higher 
than the previous one [0.83]. Therefore, the HAM-D version that mostly 
recommended is that of 17 items, because adding four items produces 
negligible reliability improvement.  
The HAM-D scores are interpreted as  
0-7 none or minimal depression 
8-17 mild depression 
18-25 moderate depression 
26+ Severe depression 
 
4. Extra pyramidal Symptoms Rating Scale: 
The Extra pyramidal Symptom Rating Scale was developed to 
assess four types of drug induced movement disorder; Parkinsonism, 
akathesia, dystonia and tardive dyskinesia .Studies found higher inter 
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rater reliability correlations in both antipsychotic induced movement 
disorders and idiopathic Parkinson disease.  
The Extra pyramidal Symptom Rating Scale specificity was 
investigated and it was found that Extra pyramidal Symptom Rating Scale 
measurement of drug induced extra pyramidal symptoms is valid and 
discriminative from psychiatric symptoms. Inter-rater reliability 
significance was demonstrated at the 0.01 level. 
5. Schedule for Assessment of Insight [SAI]: 
The SAI developed by A David is a three item rating scale used to 
evaluate insight in psychotic illness.  
This scale evaluates insight in 3 dimensions. 
1. The recognition of mental illness  
2. The ability to recognize abnormal mental events as pathological  
3. Treatment compliance.  
Responses are scored on a 0-2 scale. 
Responses are scored on 0-2 scale [0=never, 2==often] 
It has been reported to have a correlation 0.527 with the BPRS total 
and 0.525 with the Beck total. Total score is14. Higher score indicates 
better insight. 
7. Global Assessment of Functioning: 
The Global Assessment of Functioning is a modified version of the 
Global assessment Scale [GAS], first appeared in DSM-IIIR in 1914. 
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Overall function on axis V of the DSM-VI is assessed using the Global 
Assessment of Functioning scale.  
This scale may be particularly useful when the clinical progress of 
a patient needs to be assessed in global terms using a single measure. The 
Global Assessment of Functioning scale is rated with respect to 
psychological and occupational functioning only. 
The reliability ranges from 0.62 to 0.82 
These scales are administered at the time of intake of the subjects. 
The Psychotic symptom pattern and severity is measured by PANSS. The 
depressive symptoms are measured by HAM-D. This scale is widely used 
to measure the depressive symptoms in non-psychotic patients. Hence the 
Calgary Depression Scale for Schizophrenia [CDSS] is being used to 
assess the depressive symptoms in psychotic patients. 
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RESULTS  
SUMMARY OF RESULTS 
1. Socio-demographic and clinical details:  
The study group was a homogenous sample consisting of 80 patients. 
The demographic details were as depicted in Table-1 and Table-2. 
The mean age of the study sample was 31.80[SD 8.519].The mean 
educational standard in years was 7.46[SD 5.024]. 
Out of the 80 patients 57.5 percent were males and the remaining 42.5 
percent were females.50 percent of them were unmarried,43.8 percent 
were married and only 6.3 percent were separated and living alone. 
82 percent of the study population belonged to Hindu religion, 15 percent 
were Christians and 2.5 percent were Muslims. 
Half [50%] of the study group were dwelling in urban setting and 50% 
were living in rural settings. 
55% of the study group were earning below 900 rupees per month,3.8% 
were earning 900 to 3000 per month.30% of them were earning 3001 to 
9999 per month and a meager group were getting more than 10,000 
rupees per month. 
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2. Details of Illness variables: 
The detailed description of the illness variables including the type of 
Schizophrenia, number of episodes, duration of illness and number of 
hospitalization were depicted in Table-3 and Table-4. 
The mean age of onset was 25.20[SD 5.024] and mean age at first 
hospitalization was 28.5[SD 7.780] 
The mean duration of untreated psychosis was 25.51[SD38.662].The 
mean duration of the illness was 8.09[SD3.123] months. 
Table-4 describes the details of the percentage of illness parameters. 
52.5 percent of the study group was suffering from undifferentiated 
Schizophrenia and 46.3 percent belonged to Paranoid Schizophrenia 
subtype. Only 1.3 % was diagnosed to have a catatonic sub type of 
Schizophrenia. 
90% of the population had only one episode of illness during their natural 
course of the illness and 10% had more than one episode.  
3. Familial inheritance: 
The family history of Psychiatric illness, alcohol dependence and suicide 
were demonstrated in Table-5. 
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A positive family history of mood disorder or Schizophrenia 
independently were found in 10% of study design. It is worth observing 
that out of eight probands who had family history of schizophrenia, seven 
had features of depression  and out of eight who had a family history of 
schizophrenia, none had features of depression. There was a positive 
family history of suicide in 5% of first degree relatives, 3.8% of second 
degree relatives and 1.3% of third degree relatives. 
12.6% had a positive family history of alcohol dependence syndrome 
[10%, first degree relatives, 13%, second degree relatives and 13%, third 
degree relatives]. However these were not statistically significant. 
4. Psychopathology of the study group :[ Table-6[a] 
Positive symptoms, Negative symptoms and General 
Psychopathology; 
The mean total PANSS score of the study population is 52.24[normal 
baseline value-=30]. 
The mean score on sub scales were, 
PS [sum of Positive symptom Score] = 15.249 [SD 3.033]  [Range=7-49] 
NS [sum of Negative symptom score] = 11.49 [SD 3.819] [Range=7-49] 
GP [General Psychopathology Score] = 25.61[SD 4.777] [Range 16-112] 
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The cut off score for severe cases were 210.The average score for stable 
out-patients was 60-80.The score for In-patients was 80-150. 
The study group falls under the category of “mild category” in terms of 
psychopathology. 
The composite index [CI] is -9 to+18[normal range—42-42] indicating 
predominantly positive symptoms. 
4. Depressive symptoms in Schizophrenia:[Table-6[b]] 
This population had a mean Calgary depression rating scale score of 
4.46[SD6.737]. 
A score above 6 on CDSS is proposed to separate depression in 
schizophrenic population from Schizophrenia without Depression. One 
study has found optimal cut-off value of at least 7 as “Major Depression 
“in schizophrenic subjects and at least 4 to detect “Minor Depression” 
Hence the current study group qualifies for “Minor Depression” 
category. 
The mean score on the HAM-D [Hamilton Depression Rating Scale] 
measurement was 9.41. [Range=0-7]. 
A score of 8-13 on HAM-D indicates “mild” in severity of depression. 
Both the specific Calgary Depression  Scale for Schizophrenia score as 
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well as the severity in HAM-Dscale clearly depicts that the current study 
group has mild depression associated with schizophrenic 
psychopathology. 
5.  Extra pyramidal symptoms associated with schizophrenic 
symptomatology: 
[Table-6[c]] 
The mean score on extra pyramidal symptoms rating scale was below one 
in all the four subscales demonstrating that the study populations did not 
have significant extra-pyramidal symptoms during the assessment. 
6.  Functional outcome in Depression with Schizophrenia:  
Table [6b] 
The mean value on Global Assessment of Functioning Scale [GAF] was 
5.90[SD.922]. 
A GAF score of >5 indicating moderate function and the degree of 
functioning goes up above 5. 
The current study group belongs to “moderate functioning” persons 
with Schizophrenia. 
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7. Insight in depression with Schizophrenia: Table [6b] 
The mean score value on Schedule for Assessment of Insight was 
2.04[2.378]. 
The maximum total score representing the three dimensions of insight is 
24. Considering the maximal score on insight which indicates better 
insight, the study group having mean value of 2.04 indicates “poor 
insight. 
8. Correlation between demographic factors and illness 
characteristics:[ Table 11] 
The age of the subjects correlated positively with the age of onset and the 
duration of untreated psychosis [p<0.05]. 
Education in number of years had a significant negative correlation with 
age of onset of the illness [p<0.01] and HAM-D score [p<0.01]. 
Duration of untreated Psychosis had a positive relationship with negative 
symptoms score of PANSS and Global assessment of functioning [GAF] 
score at 0.05 level of significance. 
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9. Correlation between Psychopathology dimensions of 
Schizophrenia and Depression in Schizophrenia:[Table 12] 
The General Psychopathology score [GP] of PANSS had a positive 
correlation with Negative Symptom [NS] [p<0.05] and negative 
correlation with positive symptoms [PS] [p<0.01]. 
The General psychopathology [GP] score correlated positively with 
CDSS score and HAM-D score [p<0.05] 
10. Correlation between functional outcome, Insight and Depression 
in Schizophrenia: [Table 13] 
The CDSS score and HAMD Score had a significant positive correlation 
with SAI [Schedule for assessment of Insight] score [p<0.05] 
HAMD Score had a negative correlations with GAF [Global assessment 
of functioning score [p<0.05]. 
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Table-1: Socio-demographic details of the study design 
LIST OF TABLES: 
Variable N[cases] mean SD Range 
Age 80 31.80 8.519 18-58 
 Education 80 7.46 5.024 0-16 
 
Table-2: Socio-demographic details in percentage 
Variable[n=80] Frequency percentage 
GENDER 
 
Male 
 
Female 
 
 
46 
 
34 
 
 
57.5 
 
42.5 
MARITAL STATUS 
Unmarried 
Married 
Separated 
 
40 
35 
5 
 
50 
43.8 
6.3 
Religion 
Hindu 
Christian 
Muslim 
 
62 
12 
2 
 
82.5 
15 
2.5 
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Occupation 
Manual 
Unskilled 
Skilled 
 
43 
6 
17 
 
53.8 
7.5 
21.3 
Residence 
Urban 
Rural 
 
40 
40 
 
50 
50 
Income 
<900 
900-3000 
3001-9999 
>10,000 
 
44 
3 
24 
9 
 
55 
3.8 
30 
11.3 
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Table-3: Description of Illness variables 
Variable N=[80] mean SD range 
Onset age 80 25.20 5.024 13-48 
DUP 80 25.51 38.662 1-216 
Age of FH 80 28.51 7.780 3-54 
DI[months] 80 8.09 3.123 0-19 
 
DUP-Duration of Untreated Psychosis 
Age of FH-Age of First Hospitalization 
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Table-4: Frequency of illness variables. 
Variable Frequency Percentage 
Paranoid schiz 37 46.3 
Undiff. schiz 42 52.5 
Catat  schiz 1 1.3 
Ist episode 72 90 
>1episode 8 10 
 
Schiz==Schizophrenia          
Undiff==Undifferentiated 
Catat==Catatonic 
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Table-5: Family history [frequency table]. 
Variable Frequency % 
Mood disorder 8 10 
Schizophrenia 8 10 
Suicide 
1st
2
 relative 
nd
3
 relative 
rd relative 
 
8 
1 
1 
 
10 
1.25 
1.25 
Alcohol 
1st
2
 relative 
nd
3
 relative 
rd relative 
 
8 
1 
1 
 
10 
1.25 
1.25 
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Table-6[a]: mean scores of the measurements. 
Scale N=[80] mean SD Normal 
Range 
PANSS 
PS sum 
 
80 
 
15.24 
 
3.003 
  
7-49 
PANSS 
NS sum 
 
80 
 
11.49 
 
3.819 
 
7-49 
 
CI score 80 3.75 5.430 -42-+42 
GP score 80 25.61 4.777 16-112 
 
PS-Positive syndrome [P1-P7] 
NS-Negative Syndrome [N1-N7] 
CI-composite Index [P-N] 
GP-General Psychopathology 
PANSS total Score=52.24[Normal Baseline Score=30] 
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Table-6[b]: mean values of Depression Rating,  
GAF and Schedule of Assessment of insight. 
Scale N Mean SD 
CDSS score 80 4.46 6.737 
HAM-D score 80 9.41 7.833 
GAF score 80 5.90 0.922 
SAI score 80 2.04 2.378 
 
CDSS-Calgary Depression  Scale for Schizophrenia 
HAM-D-Hamilton Depression Rating Scale 
GAF-Global Assessment of Functioning 
SAI-Schedule for Assessment of Insight 
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Table-6[c]: mean values of ESRS scale. 
Scale N mean SD 
ESRS-1 80 0.10 0.409 
ESRS-2 80 0.10 0.439 
ESRS-3 80 0.00 0.000 
ESRS-4 80 0.00 0.000 
 
ESRS scale- ExtraPyramidal Symptom Rating Scale 
ESRS-1—Parkinsonism, dystonia and Dyskinesia: Questionnaire 
ESRS-2—Parkinsonism 
ESRS-3—Dystonia 
ESRS-4—Dyskinetic Movements 
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Table.7 
Test Statistics 
 
 
Mann-
Whitney 
U 
Wilcoxon W Z Asymp. Sig.  (2-tailed) 
Age 766.000 1942.000 -.020 .984 
Education 674.500 1850.500 -.927 .354 
onset age 557.500 1085.500 -2.072 .038 
Dur untre 710.500 1238.500 -.571 .568 
1st hospi 734.500 1262.500 -.330 .741 
DOI 574.000 1750.000 -1.911 .056 
PS 731.500 1259.500 -.361 .718 
NS 685.500 1861.500 -.814 .415 
CI 726.500 1254.500 -.409 .683 
GP 636.000 1812.000 -1.301 .193 
Anergia 742.000 1270.000 -.287 .774 
Thot dist 654.500 1830.500 -1.136 .256 
Activa 754.500 1282.500 -.139 .889 
Paranoid 662.000 1838.000 -1.057 .290 
Depressi 679.000 1855.000 -.979 .327 
CAL tot 671.000 1847.000 -1.086 .278 
HAM tot 740.000 1916.000 -.276 .783 
GAF 700.500 1876.500 -.704 .482 
SAI tot 642.500 1818.500 -1.265 .206 
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Table.8 
Chi-Square Tests (family history of schizophrenia) 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 1.353(b) 1 .245   
Continuity 
Correction(a) .869 1 .351   
Likelihood 
Ratio 1.361 1 .243   
Fisher's Exact 
Test    .260 .176 
Linear-by-
Linear 
Association 
1.336 1 .248   
N of Valid 
Cases 79     
 
a.  Computed only for a 2x2 table 
 
b.  0 cells (.0%) have expected count less than 5. The minimum expected 
count is 14.52. 
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Table.9 
 
Chi-Square Tests (family history of suicide) 
 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square .036(b) 1 .850   
Continuity 
Correction(a) .000 1 1.000   
Likelihood 
Ratio .036 1 .850   
Fisher's Exact 
Test    1.000 .570 
Linear-by-
Linear 
Association 
.035 1 .851   
N of Valid 
Cases 79     
 
a  Computed only for a 2x2 table 
 
b  2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 3.75. 
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Table.10 
Chi-Square Tests(family history of mood disorder) 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 4.215(b) 1 .040   
Continuity 
Correction(a) 2.820 1 .093   
Likelihood 
Ratio 4.759 1 .029   
Fisher's Exact 
Test    .061 .043 
Linear-by-
Linear 
Association 
4.161 1 .041   
N of Valid 
Cases 79     
 
 
a  Computed only for a 2x2 table 
 
b  2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 3.75. 
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Table-11: 
Pearson’s/Spearman’s[r] correlation co-efficient of demographic 
variables with disease variables [n=80] 
 Age at onset DUP HAMD score 
Age .727** .270*  
Education -.409**  -.236* 
PANSS [NS]  .267*  
GAF  .270*  
 
*correlation is significant at the 0.01 level 
**correlation is significant at the 0.05 level 
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Table-12: 
Pearsons/Spearman’s[r] correlation co-efficient of depression  
scores with mean scores on PANSS [n=80] 
 
 CDSS score HAMD score PANSS [GP] 
PANSS [PS]   -.222* 
PANSS [NS]   .333** 
PANSS [GP] .627** .570**  
 
*correlation is significant at the 0.01 level 
**correlation is significant at the 0.05 level  
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Table-13: 
Pearsons/Spearman’s[r] correlation co-efficient of mean  
scores on CDSS and HAM-D 
 
 PANSS[GP] SAI score HAM-D 
PANSS [GP]   .570** 
CDSS score .627** .464** .866** 
HAM-D score  .392**  
GAF   -.287** 
 
*correlation is significant at the 0.01 level 
**correlation is significant at the 0.05 level 
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LIST of Diagrams and Graphs 
Diagram 1 
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Diagram 2 
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Diagram 3 
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Diagram 4 
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Scatter plots 
Relationship between mean value of Duration of 
Untreated Psychosis [DUP]and Negative symptoms 
(Scatter plot 1) 
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P-value (p. <0.05) 
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Relationship between CDRS Score and Negative 
symptoms sum of PANSS (Scatterplot  2). 
 
 
 
P.Value (p. <0.01) 
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Relationship between HAMD score and GAF 
(Scatter plot 3) 
 
P.Value (p<0.01) 
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Relationship between CDRS score and Schedule for 
Assessment of Insight (Scatter plot 4) 
 
 
P.value(p-<0.01) 
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DISCUSSION: 
This study is designed to search depression as a symptom or 
syndrome in persons diagnosed to be suffering from Schizophrenia. The 
need to segregate features of Depression from the apparently inherent 
constituents of Schizophrenia viz. the negative symptoms and cognitive 
impairments on one hand and the secondary influences caused by the 
disease process other than Depression and the impact of pharmacotherapy 
on the other hand is recognised as a challenge to clinical acumen. Any 
attempt to define these features is a riddle and permits much of 
complicating overlap. Hence instruments were chosen with care to 
qualitatively differentiate these features before quantifying the 
observations. 
The scores from Calgary Depression Scale for Schizophrenia 
[CDSS], Hamilton Rating scale for Depression [HAM-D], and Positive 
and Negative Symptoms Scale [PANSS] were considered for this 
purpose.  
80 subjects of both genders attending a tertiary care centre were 
consecutively taken up for the assessment.  
Assessment of psychopathological dimension and the depressive 
symptoms were cross-sectional indicating incidence of depressive 
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symptoms at a point in time. Depression was measured based on rating 
scales of Calgary Depression scale for Schizophrenia and Hamilton 
depression rating scale. Assessment was done by two psychiatrists for 
better reliability. 
In this study population 34.5% had Depressive symptoms. Some of 
the earlier studies rated the prevalence of depression based on the 
syndromal criteria and some were based on the rating scales criteria. The 
prevalence rate ranged from 7% to 75%. [Korean AR and Lieberman et al 
1993]. 
The lowest rate was observed based on rating scale [Hirsch Sr and 
Patel M1989].The modal rate of Depression in Schizophrenia was around 
25% [Maglashan TH and Carpenter WJ et al 1976]. 
In this investigation, 30% subjects had Major Depression[>7 points] 
based on the Calgary Depression scale for Schizophrenia which is the 
sensitive measurement separating Depression as an  integral part of 
Schizophrenia from the secondary factors contributing for Depression in 
Schizophrenia. 4.5 percent of the study subjects had qualified for Minor 
Depression, scoring above 4 points in Calgary Depression  scale for 
Schizophrenia. Both major and minor category was based on the CDSS 
score. [Addington D and Tyndale EM et al 1994].  
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The psychopathological aspects of the population reveals that they 
had a mild level of psychopathology based on the PANSS total score. 
This represents the stable group of subjects on antipsychotic treatment. 
Negative symptoms in schizophrenia and depression: 
The overlay of depressive symptoms with negative symptoms were 
variously reported in schizophrenia. [Siris SG and Casey E et al 1992]. 
The major differentiating symptom was mood, which distinguishes the 
negative syndrome profile of Schizophrenia. [Siris SG 1995]. In this 
study, the depressive scores on CDSS [Calgary Depression  scale for 
Schizophrenia] and Hamilton depression rating scale had shown a 
statistically significant correlation with general psychopathology score 
of PANSS. The general psychopathology score indirectly correlates 
positively with negative symptoms scale of PANSS. 
Based on this observation, the depressive symptoms may have an 
overlay of negative symptoms of Schizophrenia rather than an 
independent syndrome of schizophrenic illness. 
Few authors have reported a positive relationship between 
depressive symptoms and positive symptoms of Schizophrenia. But in 
this study positive symptoms had negative relationship with general 
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psychopathology score which in turn has positive correlation with 
depressive scores on CDSS and HAMD. 
Depression in Schizophrenia and extra pyramidal symptoms; 
Another area of conceptual confusion has rested on extrapyramidal 
symptoms due to the apparent resemblance of symptoms and signs. The 
neurochemistry is also in close proximity. Even the pharmaco- 
therapeutic agents have some areas in common. 
No significant correlation was found between the total scores on the 
extra pyramidal symptom rating scale and severity of depression by 
Hamilton depression rating scale or Becks depression inventory.[Herald 
A and Som DS et al 2008]. Akinesia and akathesia were found to have 
confounded in the literature. [Rifkin A and Klein DF et al 1975]. 
This sample did not have significant extra pyramidal symptoms on 
the ESRS Scale indicating that there were no drug induced neurological 
side effects in the study population. This may be due to the atypical 
antipsychotic treatment or lower therapeutic maintenance dosage of both 
conventional and atypical antipsychotic medications. 
Depressive symptoms were present while on antipsychotic 
treatment. The influence of antipsychotics or the role of antipsychotic 
85 
 
medications cannot be commented in this sample as no pretreatment 
assessment is available. 
Positive correlation was found between plasma levels of 
haloperidol and depressive symptoms. [Krakowski M and volavka J et al 
19970]. 
Depression in schizophrenia and Functional Outcome: 
Depressive symptoms in schizophrenia are associated with poor 
functioning and quality of life scores. Patients with depressive symptoms 
also need more number of hospitalization and are associated with a high 
mortality rate including suicide. 
Bowie et al observed a negative correlation with functional 
outcome. Both depressive symptoms and negative symptoms were 
associated with poor functional outcome. 
In this current observation, the duration of untreated Psychosis 
[DUP] was positively correlated with negative symptoms score of 
PANSS and GAF score. 
This represents that delay in the initiation of treatment results in 
development of more negative symptoms and more functional 
impairment reflecting the functional outcome of the illness. Hamilton 
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depression rating scale score had negatively correlated with Global 
assessment of Functioning score. 
On par with the available literature, the presence of depressive 
symptoms predict an unfavourable outcome of functioning. 
Depression  in schizophrenia and Insight: 
The insight score was positively correlated with lower mood in 
many studies. Poor insight in fact protects against depression. [Ambalam 
P and Vadapathy P  2012]. 
In analogy with the previous observations, the current observation 
also reports that a statistically positive correlation between CDSS score, 
HAMD score and the scores on SAI [schedules for assessment of Insight] 
exists. 
The degree of insight measured in three dimensions by using the 
SAI scale indicating direct correlation with depression rating scale scores. 
Schizophrenic patients are prone to develop depression when they regain 
their insight during the course of illness. 
All the subjects in this study were having mild psychopathology in 
terms of rating on PANSS but their mean score on insight was very low 
indicating poor insight Schizophrenia group. The poor insight in the 
87 
 
present group may be the reason for lower degree of depressive 
symptoms leaving them in mild depression category. 
Prevalence of Depressive symptoms in Schizophrenia is higher in 
patients who have a positive family history of mood disorder or suicide or 
alcohol dependence. It is evident from earlier studies, that a familial 
transmission is common in major affective disorders. Hence it seems very 
much reasonable to believe that the depressive symptoms appearing in 
patients with Schizophrenia might be the result of a familial liability for 
affective disorders [17]. 
Going by the stress-vulnerability model, we can arrive at the 
conclusion that probably the family history of affective disorders lowers 
the threshold for developing depressive symptoms in these patients. 
Similar findings were evident in the researches 
done by Subotnik et al 1997, Kendler and Hays 1983.  It is possible that 
this affective burden does not have a say in the psychotic process per se 
but instead gives it an affective colouring. It may be over simplification 
to conclude that Depression with genetic transmission will find its way 
with families where the genetic load is severe, with more number of 
depressed persons in its fold. It is worth recollecting at this point Slater’s 
interpretation that depressive symptoms in relatives, particularly parents 
of the patient may be a phenotypic expression of the genotype 
schizophrenia. 
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Antipsychotics and depression in Schizophrenia 
Patients on atypical antipsychotic for more than a month have low 
scores on CDSS scores than patients who have been on typical 
antipsychotic. This is in agreement with various studies conducted by 
Marder et al, 1997, Tollefsonn et al, 1998, Emsley et al 2003 and Mauri 
et al 2008 who unanimously reported that the second generation 
antipsychotics have been associated with reduced symptoms of 
Depression.  
There may be various probable reasons for this superiority of 
atypical antipsychotics in the treatment of depressive symptoms in 
Schizophrenia .One way of looking at it is that, since the atypical 
psychotics do not exert their antipsychotic action exclusively by 
dopamine blockade, they rely on actions through various other receptors 
for their therapeutic effect and hence their chances of producing the 
phenomenon of neuroleptic induced dysphoria is meagre.  
The atypical antipsychotics have a better side effect profile [Casey 
D E1997 , Tandon R 1997, Couinard G 1993, Marder S R 1994] and 
hence the compliance with these medications are better on the long run 
[Rosenheck R 1997,Song F 1997,Naber D 1998 ] thereby decreasing the 
incidence of Depression heralding the prodrome of a psychotic relapse.  
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These antipsychotics exert their action on a diverse set of receptors 
including dopaminergic, serotonergic, histaminergic, muscarinic and 
alpha 1 nor- adrenergic receptors. This diversity of actions at various 
receptors is probably responsible for their anti depressant action 
[Tollefson GD 1998, Waddington J L 1997].  
Studies focussing  on both Depression [Pandey G N et al 1990 ]and  
Schizophrenia [ Kahn R S et al 1993] have concentrated on the 5-HT2 
binding site , as this can accelerate the dopamine flow across the synapse 
through its potential to produce presynaptic inhibition. But it would be 
too premature to come to a conclusion that this is the only site of action, 
and probably much more research is needed in this area. As of now, it is 
prudent to understand that the various atypical antipsychotics vary in their 
level of actions at various receptors and that this eventually results in a 
wide variation in their antidepressant efficacy. They therefore should not 
be assumed to be a homogeneous group.  
It would be inappropriate to conclude from the  effect –or lack of 
effect – found with one agent  to apply to other atypical agents. Many 
molecules in this cluster have precise antidepressant activity in lower 
doses.  In this study, the subjects received either typical or atypical 
antipsychotic drugs or both  in moderate doses. Patients  on medications,  
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did not have significant extrapyramidal symptoms and had a significant 
incidence of depression.  
Based on this observation we may be justified in concluding that, 
the association between depression and Schizophrenia is independent of 
the extrapyramidal symptoms and antipsychotic medications. 
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Some questions arise as a result of this experience. 
a. Can we consider as genetic conglomeration by chance association 
what we saw as depression in Schizophrenia? 
b. Is depression a part and parcel of Schizophrenia? 
c. Is it possible that Depression and Schizophrenia are at the two ends of 
a continuum? 
d.  Do we have to treat depression in schizophrenia with anti 
depressants? Will all the antidepressants be qualified for this purpose? 
Already some suggestion indicating benefit with Escitalopram [not 
Citalopram] and Fluvoxamine is available. If it is so, the widely held 
Dopamine theory on Depression and Schizophrenia need to go back 
stage, for we have to mix poison and the potion. 
e. Or is it sufficient to treat Schizophrenia? Would depression in 
Schizophrenia clear? 
f. Is it necessary to suggest even if remotely, the possibility to discard 
the Kraepelinean dichotomy? 
g. Are we going back or forward? 
h. Considering stress of Depression as a precipitator of psychosis with 
positive symptoms, will it be worth treating adolescent depressions 
more aggressively with a view to prevent a psychotic breakdown, at 
least in persons with high risk family history? What pharmacological 
strategy can be advantageous? Anti depressants or Serotonin- 
Dopamine receptor Antagonists? 
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STRENGTHS & LIMITATIONS OF THE STUDY 
STRENGTHS: 
1. Calgary Depression scale for Schizophrenia which has been 
found to be particularly useful in identifying and quantifying the 
depressive features in patients with schizophrenia has been 
used. 
2. An adequate number of patients were included into the study to 
increase the statistical relevance of the study. 
3. The diagnosis of schizophrenia was made by two independent 
observers. 
4. No cut off point was used to assess the depressive symptoms. A 
dimensional approach was used and not the categorical 
approach. 
5. This study had equal number of patients from rural and urban 
background. 
LIMITATIONS:  
1. No control group was used. 
2. No randomisation done in the selection of cases. 
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3. Patients with positive symptoms are more likely to come to the 
hospital and hence the sample contains more patients with positive 
symptoms. 
4. All samples were collected from a tertiary centre and hence may 
not be applicable to the community. 
5. We recruited patients who approached the hospital for treatment 
and so it is not a genuine epidemiological sample .This also 
increases the so –called  Berkson’s bias –the more conditions a 
patient suffers from, the higher the likelihood of seeking treatment- 
which leads to an over-representation of patients with multiple 
diagnosis in samples recruited from clinical settings . 
6. No drug naive patients in the sample – to help exclude the 
influence of neuroleptic drugs in mimicking symptoms of 
depression. 
7. The group was heterogeneous with respect to age, gender, duration 
of illness, type of Schizophrenia and the duration of treatment. 
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CONCLUSION 
The extent of psychiatric co-morbidity in Schizophrenia is often not 
appreciated; in part this is because of a heritage of an essentially 
hierarchial approach to psychiatric diagnosis, where Schizophrenia 
trumps the diagnosis of Depression. However it is essential to address the 
depressive symptoms in Schizophrenia as these are common, tend to 
worsen the longitudinal course of Schizophrenia and also results in an 
increase in morbidity and mortality. 
The various factors that might mediate depression in Schizophrenia 
include 
• Psychosocial  stressors [ egs family stress, loss of role] 
• Social factors [unemployment, lack of social network etc] 
• Adjustment to diagnosis 
• Adjustment to the social stigma 
• Alcohol and illicit substance use 
• Non compliance with antipsychotic medication 
• Direct dysphoric effect of antipsychotic medication 
• Extrapyramidal side effects of antipsychotic medication 
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Depression in Schizophrenia is reported to be associated with 
worse outcome, impaired functioning and personal suffering. Depression 
is also linked with higher rates of relapse, rehospitalisation and even 
suicide. This study however did not go into the therapeutic aspects. 
Though Psychiatrists unanimously agree that Depression in 
Schizophrenia is associated with considerable clinical burden, there is no 
consensus regarding the best treatment strategy or a clear indication for 
initiating specific treatment. Thus the sensitive and specific assessment of 
depressive symptoms in Schizophrenia is important for diagnostic, 
prognostic, and therapeutic reasons. 
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Future directions 
I. Prospective study following adolescent Depression to 
determine the frequency of conversion to Schizophrenia is 
imminent. 
II. Study of patients in the acute phase of psychosis to 
differentiate and elicit depressive symptoms 
III. In depth study of the qualitative assessment of depressive 
symptoms in Schizophrenia. 
IV. Therapeutic trials with addition of antidepressants and 
without them. 
V. Study of suicide – attempt and completion and its 
relationship to presence of Depression or absence of it, and 
to determine whether suicide in Schizophrenia is more 
impulsive or premeditated? 
VI. Treatment trials involving antidepressants to treat depression 
in prodrome to observe the efficacy to abort Psychotic break 
down. 
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  APPENDIX 
 
APPENDIX - I 
 
SOCIO DEMOGRAPHIC DATA SHEET  
   
Serial No: ____                     OP. No: ________________  
Name: ____________________    Age:                    Sex:         
Marital status:    Unmarried              Married             Separated  
Religion:           Hindu        Christian       Muslim           Other  
Education in Years: _________               Employment:  Yes      No  
Nature of Work:     Manual        Unskilled         Skilled  
Income Class:           <900           900 - 3000    3001 - 9999        > 10,000   
Residence:          Urban         Rural  
 
CLINICAL DATA SHEET  
Type of Schizophrenia: Paranoid    Undifferentiated    Catatonic   
                                          Residual     Disorganized           Other  
First Episode:         Yes          No             Age at Onset: _____________  
Duration Untreated: _____________     Age at First Hospitalisation: _____________  
Number of Admissions: ___   Duration of Illness :< 2 yrs, 2-5yrs, >5 yrs   in months 
____ 
Family History:        Yes         No  
Mood disorder 
Suicide 
Alcohol Dependence   
Handedness: Right     Left  
Current Treatment:  Typicals   Atypicals    
Last Prescription: 
H/o treatment with antidepressants:  
H/o treatment with Lithium: 
Current Substance Use:   Yes         No 
Medical illness: 
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APPENDIX - II 
 
POSITIVE  AND  NEGATIVE  SYNDROME  SCALE 
 
 
  0 1 2 3 4 5 6 
POSITIVE   SYMPTOMS       
P1 DELUSIONS        
P2 CONCEPTUAL 
DISORGANISATION 
       
P3 HALLUCINATORY  
BEHAVIOUR 
       
P4 EXCITEMENT        
P5 GRANDIOSITY        
P6 SUSPICIOUSNESS        
P7 HOSTILITY        
NEGATIVE  SYMPTOMS       
N1 BLUNTED AFFECT        
N2 EMOTIONAL 
WITHDRAWAL 
       
N3 POOR RAPPORT        
N4 PASSIVE /APATHETIC 
SOCIAL WITHDRAWAL 
       
N5 DIFFICULTY IN 
ABSTRACT THINKING 
       
N6 LACK OF SPONTAENITY 
AND FLOW OF 
CONVERSATION 
       
N7 STEREOTYPED THINKING        
GENERAL  PSYCHOPATHOLOGY SYMPTOMS      
GI SOMATIC CONCERN        
G2 ANXIETY        
G3 GUILT  FEELING        
G4 TENSION        
G5 MANNERISMS/POSTURING        
G6 DEPRESSION        
G7 MOTOR  RETARDATION        
G8 UNCOOPERATIVENESS        
G9 UNUSUAL THOUGHT 
CONTENT 
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G10 DISORIENTATION        
G11 POOR ATTENTION        
G12 LACK OF INSIGHT AND 
JUDGEMENT 
       
G13 DISTURBANCE OF 
VOLITION 
       
G14 POOR IMPULSE CONTROL        
G15 PREOCCUPATION        
G16 ACTIVE SOCIAL 
AVOIDANCE 
       
 
 
PANSS  PROFILE SUMMARY 
 RAW  
TOTAL 
PRECENTILE RANGE 
SCALES    
POSITIVE  SYNDROME  [sum of P1 to P7]    
NEGATIVE  SYNDROME [sum of N1 to N7]    
COMPOSITE  INDEX [PS – NS ]    
GENERAL  PSYCHOPATHOLOGY  [sum of 
G1 to G 16] 
   
 
CLUSTER  SCORES 
ANERGIA N1 + N2 + G7 + G10  
THOUGHT  DISTURBANCE P2  + P3 + P5 + G9 
ACTIVATION P4 + G4 + G5 
PARANOID / BELLIGERANCE P6 + P7 + G8 
DEPRESSION G1 + G2 + G3 + G6 
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APPENDIX - III 
 
 
THE CALGARY DEPRESSION SCALE FOR  
SCHIZOPHRENIA [CDSS] 
 
 
 
  0 1 2 3 
1 Depression     
2 Hopelessness     
3 Self depreciation     
4 Guilty ideas of 
reference 
    
5 Pathological guilt     
6 Morning 
depression 
    
7 Early wakening     
8 Suicide     
9 Observed 
depression 
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APPENDIX - IV 
 
HAMILTON DEPRESSION RATING SCALE 
 
 
S.NO ITEMS 0 1 2 3 4 
1 DEPRESSED MOOD      
2 FEELING OF GUILT      
3 SUICIDE      
4 INSOMNIA[ EARLY]     
5 INSOMNIA [MIDDLE]    
6 INSOMNIA [LATE]    
7 WORK AND ACTIVITIES     - 
8 RETARDATION      
9 AGITATION     
10 ANXIETY [PSYCHIC]      
11 ANXIETY [ SOMATIC]      
12 SOMATIC SYMPTOMS-GI     
13 SOMATIC SYMPTOMS- 
GENERAL 
   
14 GENITAL SYMPTOMS    
15 HYPOCHONDRIASIS     - 
16 LOSS OF WEIGHT     - 
17 INSIGHT     
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APPENDIX - V 
 
GLOBAL ASSESSMENT OF FUNCTIONING [GAF] SCALE  
100-91: Superior functioning .No symptoms.  
90-81: Absent or minimal symptoms, no more than everyday problems or concerns  
80-71: symptoms are they are transient and expectable reactions to psychosocial 
stressors, mild social dysfunction 
70-61: Some mild symptoms OR some difficulty in social, occupational, or school 
functioning, but generally functioning pretty well. 
60-51: Moderate symptoms OR moderate difficulty in social, occupational, or school 
functioning.  
50-41: Serious symptoms OR any serious impairment in social, occupational 
functioning  
40-31: Some impairment in reality testing or communication OR major impairment in 
several areas such as work or school, family relations, judgment, thinking, or mood  
30-21: Behavior is considerably influenced by delusions or hallucinations OR serious 
impairment in communication or judgment OR inability to function in almost all 
areas.  
20-1: Some danger of hurting self or other OR occasionally fails to maintain minimal 
personal hygiene OR gross impairment in communication.  
10-1: Persistent danger of severely hurting self or others OR persistent inability to 
maintain minimal personal hygiene OR serious suicidal act with clear expectation of 
death.  
0: Inadequate information. 
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APPENDIX - VI 
 
SCHEDULE FOR ASSESSMENT OF INSIGHT 
1a. Does patient accept treatment? 
1b. Does patient ask for treatment unprompted? 
2a. Ask patient “Do you think you have illness?” or “Do you think there 
is something wrong with you?” 
2b. Ask the patient “Do you think you have mental/psychiatric illness?” 
2c.Ask patient “How do you explain your illness?” 
3a. Ask patient “do you think the belief that [insert specific delusion] is 
not really true/happening? Or “Do you think that... [insert specific 
hallucination] is not really there / happening?” 
3b. Ask patient “How do you explain these phenomena [the belief that 
hearing that voice /seeing that image, etc]?” 
 
 
 0 1 2 
1a    
1b    
2a    
2b    
2c    
3a    
3b    
 
Total score = 
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APPENDIX - VII 
 
EXTRAPYRAMIDAL   SYMPTOM   RATING   SCALE 
 
I.PARKINSONISM, DYSTONIA AND DYSKINESIA:QUESTIONAIRRE 
 
 
  0 1 2 3 
1 Impression of slowness or weakness: difficulty in 
carrying out routine tasks. 
    
2 Difficulty walking or with balance     
3 Difficulty swallowing or with talking     
4 Stiffness, stiff posture     
5 Cramps or pains in limbs, back or neck     
6 Restless,nervous,unable to stand still     
7 Tremors,shaking     
8 Oculogyric crisis or abnormal sustained posture     
9 Increased salivation     
10 Abnormal involuntary movements of extremities 
or trunk 
    
11 Abnormal involuntary movements of 
tongue,jaw,lips or face 
    
12 Dizziness when standing up     
 
II. PARKINSONISM : EXAMINATION 
 
 
  0 1 2 3 4 5 6 
1 Expressive automatic 
movements 
       
2 Bradykinesia        
3 Rigidity        
4 Gait & posture        
5 Tremor        
6 Akathesia        
7 Sialorrhea        
8 Postural instability        
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III. DYSTONIA : EXAMINATION 
 
ACUTE TORSION DYSTONIA 
  0 1 2 3 4 5 6 
1 Right upper limb        
2 Left upper limb        
3 Right lower limb        
4 Left lower limb        
5 Head        
6 Jaw        
7 Tongue        
8 Lips        
9 Eyes        
10 Trunk        
11 Other        
                                                                                                  
TOTAL = ____ 
 
 
NON ACUTE  OR  CHRONIC 
 
 
  0 1 2 3 4 5 6 
1 Right upper limb        
2 Left upper limb        
3 Right lower limb        
4 Left lower limb        
5 Head        
6 Jaw        
7 Tongue        
8 Lips        
9 Eyes        
10 Trunk        
11 Other        
                                                                                                   
TOTAL = ____ 
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IV. DYSKINETIC MOVEMENTS : EXAMINATION 
 
  0 1 2 3 4 5 6 
1 Lingual movements        
2 Jaw movements        
3 Bucco-labial movements        
4 Truncal movements        
5 Upper extremities        
6 Lower extremities        
7 Other involuntary movements        
 
 
 
 
 
GLOBAL ITEMS 
V. Clinical global impression of severity of Parkinsonism  ____ 
VI .Clinical global impression of severity of Dystonia         ____ 
VII.Clinical global impression of severity of Dyskinesia      ____ 
VIII.Clinical global impression of severity of Akathesia      ____ 
 
 
 
STAGE OF PARKINSONISM 
IX. Stage of parkinsonism   ____ 
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APPENDIX - VII 
 
INFORMATION SHEET 
 
 
• You have been accepted into the study. 
• We are conducting a study on Frequency and Characterization of 
Depressive symptoms in Schizophrenia in patients attending 
Institute of Mental Health, Chennai and for that your Participation 
may be valuable to us. 
• The purpose of this study is to identify the frequency and 
characterisation of depressive symptoms in Patients with 
Schizophrenia. 
• We are selecting certain cases and if you are found eligible, we 
may be getting certain details from you which will not affect your 
final report or management. 
• The privacy of the patients in the research will be maintained 
throughout the study.  
• In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
• Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
114 
 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
• The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
 
 
 
Signature of investigator                                 Signature of participant 
 
Date: 
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INFORMED CONSENT FORM 
 
Title of the study: “Frequency and Characterization of Depressive 
symptoms in Schizophrenia”. 
Name of the Participant: 
Name of the Principal [Co-Investigator]:  
Name of the Institution: Institute of Mental Health,Chennai 
Documentation of the informed consent 
I _____________________________ have read the information in this 
form [or it has been read to me]. 
 I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “Frequency and 
Characterization of Depressive symptoms in Schizophrenia”. 
1. I have read and understood this consent form and the information 
provided to me. 
2 I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator. 
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5. I have been informed the investigator of all the treatments I am taking 
or have taken in the past________ months including any native 
[alternative] treatment. 
11. I am also aware that the investigator may terminate my participation 
in the study at any time, for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the 
information obtained from me as a result of participation in this study to 
the regulatory authorities, Govt. agencies, and IEC. I understand that they 
are publicly presented. 
13. I have understood that my identity will be kept confidential if my data 
are publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact 
the investigator. By signing this consent form I attest that the information 
given in this document has been clearly explained to me and understood 
by me, I will be given a copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant [or legal 
representative if participant incompetent] 
Name _________________________ Signature_________________ 
Date________________ 
117 
 
 
Name and Signature of impartial witness [required for illiterate patients]: 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
Name _________________________ Signature_________________ 
Date_______________ 
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BWônf£ RLYp Rôs 
BnYô[o   : 
TeúLtTô[o ùTVo  : 
RûXl×  : U]£ûRÜ úSô«u U]úNôo®u A±Ï±Ls  
                         ùRuTÓRÛm ARu RuûUÙm. 
BWônf£«u úSôdLm : 
U]£ûRÜ úSôVô°L°Pm U]úNôoÜ úSôn A§LUôL LôQlTÓ¡\Õ. 
CkúSô«u R²jRuûUûV LiP±YúR CkR Bn®u úSôdLUôÏm. 
RôeLs CkR UÚjÕY Bn®p LXkÕ ùLôsÞUôß AûZd¡ú\ôm. CkR 
BnYô]Õ GkRùYôÚ UÚjÕY RûXÂÓm CpXôRÕ. 
C§p EeLÞdÏ GkRùYôÚ BRôVúUô ApXÕ BTjúRô CÚdLôÕ. 
GeLs ûUVj§p SûPùT\ CÚdÏm Ko BWônf£dÏ EeLs JjÕûZl×m, 
Jl×RûXÙm úYiÓ¡ú\ôm. 
Ø¥ÜLû[ ApXÕ LÚjRLû[ ùY°«Óm úTôúRô ApXÕ 
BWônf£«uúTôúRô ReL[Õ ùTVûWúVô ApXÕ AûPVô[eLû[úVô 
ùY°«P UôhúPôm GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
CkR BWônf£«p TeúLtTÕ ReLÞûPV ®ÚlTj§u úT¬p Rôu 
CÚd¡\Õ. úUÛm ¿eLs GkúSWØm CkR BWônf£«­ÚkÕ ©uYôeLXôm 
GuTûRÙm ùR¬®jÕdùLôs¡ú\ôm. 
CkR £\l×l T¬úNôRû]L°u Ø¥ÜLû[ Bn®u Ø¥®uúTôÕ 
ReLÞdÏ A±®lúTôm GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
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Jl×Rp T¥Ym 
GuTY¬u UL]ô¡V 
Guàm Sôu ‘ U]£ûRÜ úSô«u U]úNôo®u A±Ï±Ls ùRuTÓRÛm 
ARu RuûUÙm” Tt±V Ru]ôoYÚdLô] RLYp Rôû[ T¥jÕsú[u. 
CkR Bn®p TeÏùT\ Sôu RÏ§ Es[Yo Guß BnYô[oLs 
Ø¥ùYÓjRôp, Sôu Bn®p TeÏ ùTÚúYu. úUÛm BWônf£ 
¨×QoLÞPu CkR Bn®u úSôdLm, CRu Y¯Øû\Ls G§oúSôdÏm 
TVeLs, TôÕLôTl× Y¯Øû\Ls, BnÜ TôPeLû[ Ï±jÕm, E¬ûULû[d 
TôÕLôlTÕ Ï±jÕm LXkÕûWVô¥Ùsú[u. G]dÏ GÝm úLs®Lû[d 
úLhÓ AYt±tÏ §Úl§LWUô] T§pLs A°dLlThPÕ, GÝjÕ êXUôLÜm 
T§pLs A°dLlTÓm GuTûR ×¬kÕ ùLôiÓsú[u. 
G]Õ ®ÚlTj§u úT¬úXúV Sôu CkR Bn®p TeúLt¡ú\u. Gu]ôp 
C§p TeúLtLôUp ®X¡d ùLôs[Üm ùNnVXôm GuTûR ×¬kÕ 
ùLôiÓsú[u. úUÛm GkR JÚ LôWQj§tLôLÜm, CkR Bn®­ÚkÕ 
Gu]ôp Sôu ®ÚlTlThPôp ®X¡d ùLôs[ Ø¥Ùm GuTûRÙm 
A±kÕsú[u. 
CkR Bn®p Sôu JÚ BnÜ ùNnVlTÓm STWôL CÚkRôp G]Õ 
E¬ûULs Ï±jÕ HúRàm úLs®Ls GÝm©]ôp. Sôu BWônf£Vô[oLû[ 
GkR úSWØm ùRôPo× ùLôiÓ NkúRLeLû[ ¨Yoj§ ùNnÕ ùLôsúYu. 
úUÛm CkR Bn®p JÚ TeúLtTô[o Gu\ Øû\«p NhPj§tÏ 
úRûYlTÓm NkRolTeLû[j R®W ©\ NUVeL°p CkR BnÜj ùRôPoTô] 
G]Õ AûPVô[m UÚjÕY BYQeLs Utßm RLYpLs WL£VUôL 
ûYdLlTh¥ÚdÏm GuTûR Sôu A±kÕùLôiÓsú[u. 
CkR BnÜ Utßm C§Ûs[ TVuLs Ï±jÕ Aû]jÕ RLYpLû[Ùm 
Sôu ØÝûUVôL A±kÕùLôiÓ, ARuT¥ BnÜ Y¯Øû\Lû[ 
úUtùLôs[ Sôu Jl×Rp A°d¡ú\u. CkR Jl×RpT¥Yj§p SLp 
Ju±û] Sôu ùTtßdùLôiúPu. 
TeúLtTô[o ùTVo  : 
ûLùVôlTm   : 
Sôs    : 
ØRuûU BnYô[o  : 
ûLùVôlTm   : 
Sôs    : 
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